Please assess the completion status of the following clinical trial:

Trial Title: Antibody Production in Immune Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Individuals being evaluated by NIH investigators for known or suspected primary immune disorders.~Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for at least 21 days prior to receipt of each vaccine and for the duration of study participation.~EXCLUSION CRITERIA:~Documented HIV infection.~Active malignancy.~Immunosuppressive therapy, other than steroids.~Symptomatic cardiac disease or ongoing treatment for it.~Pregnant or lactating women (due to restrictions on use of vaccines).~Surgery during the two weeks prior to entry.~Serious, ongoing, or uncontrolled infections.~Platelet count less than 40,000/microL or other coagulation disorder.~Any other major illness that, in the investigator's judgment, may substantially increase the risk associated with the patient's participation in this study.~History of previous systemic reaction to the particular vaccine product being considered for administration.~For RabAvert, persons known to be sensitive to:~* Processed bovine gelatin~* Chicken protein~* Neomycin~* Chlortetrycyline~* Amphotericin B~For Prevnar, persons with know or possible latex sensitivity.~The effects of the vaccines on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for at least 21 days prior to each vaccine and for the duration of study participation. Females of child bearing age will have a pregnancy test prior to each vaccination. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform study staff and her primary care physician immediately.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pneumococcal Vaccine (Type: ACTIVE_COMPARATOR): To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
- Rabies Vaccine (Type: ACTIVE_COMPARATOR): To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.

Based on this trial design, predict the completion outcome and termination type (if applicable).